Human angiotensinogen (AGT) gene promoter polymorphisms (GÀ217A; AÀ20C; GÀ6A) influence AGT transcription in vitro and have been implicated in the genetics of essential hypertension. We analysed the association among AGT promoter variants and AGT mRNA levels in human kidney and visceral adipose tissue (VAT) in vivo. Samples of kidney and VAT were obtained from 35 consecutive patients undergoing renal surgery. The AGT gene promoter of each patient was sequenced to identify variants. AGT gene expression was studied by real-time PCR TaqMan assay. Clinical data obtained before surgery were also considered in the statistical analysis. Two new polymorphisms at À175 and at À163 were identified. Although AGT expression was significantly higher in VAT than in the kidney, when both variants were present together AGT expression in VAT was about fivefold lower (P ¼ 0.033) than in the wild haplotype. This lower AGT expression in VAT suggests that the proximity and linkage of À175A and À163A variants might destabilize the binding of specific transcription factors to an acute-phase responsive element 3. Among the known AGT promoter variants, only À20C SNP has an important effect on tissue-specific differential AGT expression in the human tissues studied, inducing a 3.8-fold increase in AGT mRNA localized only in the kidney medulla (P ¼ 0.038). The other known polymorphisms (GÀ6A; GÀ217A) were not associated with different levels of AGT expression. Our results support the hypothesis that some human AGT promoter variants influence transcriptional activity in a tissue-specific way in humans.
Introduction
The renin-angiotensin system (RAS) plays a critical role in sodium handling and blood-pressure regulation; therefore RAS genes have been thoroughly investigated as candidates for essential hypertension. The most relevant RAS gene in the genetics of hypertension seems to be the angiotensinogen (AGT) gene, the precursor of angiotensin II (AngII) and other related vasoactive peptides. [1] [2] [3] Early studies focused on coding polymorphisms, and the 235T AGT allele has been associated with AGT plasma levels and hypertension. 1, 4 Variants in the promoter region of the AGT gene, altering the binding of specific transcription factors, may change transcriptional activity. The À6A promoter variant is in linkage with the 235T variant, suggesting that the increased AGT plasma levels in 235T carriers could be due to an increased transcriptional activity. 5 Nevertheless, the GÀ6A SNP association with blood pressure has been disputed 6 and was also questioned in a recent meta-analysis. 7 On the contrary, À20 and À217 promoter SNPs have better documented effects on AGT transcription and were also associated with hypertension in most studies. 8, 9 Indeed, Dickson et al. 10 showed that, in vitro, À20 and À217 SNPs had the strongest influence, increasing AGT transcription in cell lines derived from human liver, human kidney and mouse adipocyte. Nevertheless, the significance of specific promoter variants on AGT gene expression in vivo in human tissues, particularly in the kidney and adipose tissues, is still unclear.
For instance, AGT synthesized by adipose tissue not only contributes to increase local AngII concentration but is also released into the circulation, leading to dysregulation of systemic RAS activity, thus contributing to the increased blood pressure of patients with visceral obesity. 11, 12 A mice model with a transgenic human AGT gene had increased AGT expression only in visceral adipose tissue (VAT), including the perirenal depot, after a diet-induced obesity. 13 In the kidney, a localized increase of AGT transcription may lead to an increased local AngII production with systemic effects due to the quantitative influence on tubular sodium re-absorption. Indeed, intrarenal AGT mRNA and protein have been localized mainly in proximal tubular cells, 14, 15 and the high levels of intratubular and urinary AngII derive from locally synthesized AGT. Moreover, AngII plays an important role even in kidney medulla by the direct, aldosterone-independent regulation of the sodium epithelial channel in the collecting ducts, 14 a key final step in sodium and blood pressure control.
Thus, a genetic-driven increase in AGT mRNA may have very important consequences even when expressed only in specific tissues. Therefore, we studied the relationship between AGT promoter variants and AGT expression in human kidney cortex, kidney medulla and VAT to verify whether AGT promoter variants may be associated with tissuespecific AGT expression levels in humans in vivo.
Methods

Patients and human tissue samples
The study protocol was reviewed and approved by our local ethics committee and written informed consent was obtained from all patients. The study comprised 35 consecutive patients undergoing radical nephrectomy for localized clear-cell renal-cell carcinoma (without any evidence of local or metastatic cancer spread: T1/T2, N0, M0) at the 'Ospedali Riuniti' University Hospital of Ancona, Italy, between February 2006 and February 2007. All patients were white Caucasians with Italian ancestry. Clinical data were collected before surgery and all women (n ¼ 9) were in menopause and free from hormone replacements, contributing to lessen cardiovascular differences and to increase the homogeneity of the studied population. None had severe renal damage (plasma creatinine o1.5 mg per 100 ml in men and o1.4 mg per 100 ml in women). Only one patient had diabetes mellitus type 2 (treatment with diet therapy). Oral medications were stopped at least 12 h before surgery.
Samples of perirenal adipose tissue, kidney cortex and kidney medulla (from the intact portion of the removed kidney, at least 3 cm away from the localized intracapsular carcinoma) were collected from all patients. Tissue samples were then snapfrozen in liquid nitrogen and stored at -80 1C until RNA extraction.
Genotyping
To evaluate the presence of the most relevant known human AGT promoter variants, we analysed sequences from À306 to þ 36 of the AGT gene (GenBank accession number NM_000029). DNA was extracted from peripheral blood cells using the NucleoSpin Blood Kit (MACHEREY-NAGEL GmbH & Co, Duren, Germany) following the kit procedure.
In all, 40 ng of genomic DNA was amplified by PCR (using 5 0 -GTCACACACCTAGGGAGATGCT-3 0 and 5 0 -CCTTCTGCTGTAGTACCCAGAAC-3 0 as forward and reverse primers, respectively). The PCR products (342 bp) were purified by agarose gel electrophoresis and eluted using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Cycle sequencing (96 1C for 10 s, 50 1C for 5 s, 60 1C for 4 min, for 25 cycles) was carried out on both strands using the DNA sequencing kit, Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Warrington, UK). The reactions were purified by DyeExTM Spin Kit (Qiagen), and subjected to automated capillary sequencing (ABI PRISM 310 Genetic Analyzer, Applied Biosystems). Sequences were analysed on electropherograms by Sequencing Analysis 5.2 Software (Applied Biosystems).
Genotype analysis was also carried out in 110 Caucasian young healthy patients (mean age 32.3 ± 2.4 years) recruited during the follow-up of the Ancona Hearth Doctor Study (AHDS), whose protocol has been described earlier. 16 This genotyping of healthy subjects was performed in order to exclude the hypothesis that some variants might be present and/or more frequent specifically in patients with kidney cancer.
Gene expression
Total RNA was extracted from tissue samples after homogenization in guanidine thiocyanate buffer and CsCl gradient modified as reported previously. 17 RNA (1.5 mg) was reverse-transcribed with highcapacity cDNA reverse transcription kits with RNase Inhibitor (Applied Biosystems).
Real-time gene expression analysis of human AGT was carried out with TaqMan Gene Expression Assay (Hs00258938_m1; Applied Biosystems, Weiterstadt, Germany) using an ABI 7300 for real-time PCR (Applied Biosystems, Darmstadt, Germany) with the standard curve method. Differences in starting total RNA and the different efficiency of cDNA synthesis among samples were normalized using GAPDH expression as housekeeping control gene. As a further semiquantitative internal control, 18S rRNA was also amplified to normalize the results because of possible differences in GAPDH expression. There were no differences in the results when normalized either with GAPDH or with 18S rRNA, and data in the figures were then reported normalized for GAPDH. Gene expression levels were analysed using GENEX (Gene Expression Macro Software supplied by BioRad, Hercules, CA, USA) and were reported as arbitrary units (AU).
Statistical analysis
Differences in AGT expression levels among tissues were evaluated using one-way analysis of variance (ANOVA) test followed by Bonferroni's post hoc t-test. Analysis of variance adjusting for covariates (age, gender, body mass index (BMI)) was used to compare AGT gene expression across AGT genotypes. The prevalence of AGT promoter variants between hypertensives and normotensives was evaluated by w 2 -test. As some patients (n ¼ 12) were treated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), which, at least in theory, might affect AGT expression levels, the presence or absence of these drugs was introduced as a further covariate. Statistical analysis was carried out with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL, USA) and a level of Po0.05 was considered as significant. Hardy-Weinberg equilibrium (HWE) was calculated using w 2 -test.
Results Table 1 shows the clinical characteristics of 35 consecutive studied patients.
The distribution of the AGT variants among our patients is reported in Table 2 .
Sequence analysis showed the presence of two new G-A SNPs located at À175 and at À163 (Figures 1a and b) . We also analysed 110 healthy Caucasian subjects (mean age 32.3 ± 2.4 years) because these SNPs were not reported previously and also in order to exclude the presence of the two new SNPs only in patients with renal carcinoma. Frequencies of 7.3% for À163A heterozygotes and 10.9% for À175A heterozygotes were found in this healthy population. The HWE was respected for both variants (À175, P ¼ 0.55; À163, P ¼ 0.69).
The comparative expression levels of AGT gene in the human kidney cortex, kidney medulla and VAT suggested that the VAT is an important source of AGT. AGT expression was significantly higher (about fivefold) in VAT than in the kidney cortex and medulla (P ¼ 0.006 and P ¼ 0.003, respectively), whereas the cortex and medulla expressed similar levels of AGT ( Figure 2) .
Subjects with the known À20C variant had a 3.8-fold higher AGT expression localized only in the kidney medulla (P ¼ 0.038) when compared with À20A homozygotes (Figure 3a) . No significant effects were identified on AGT mRNA levels in the kidney cortex and adipose tissue (Figure 3a) .
The other known SNPs (À6AG; À217GA) were not associated with significantly different AGT expression in the tissues studied (Figures 3b and c) .
When the new À175A and À163A variants were present together in a common haplotype (n ¼ 16), they were associated with an AGT expression in VAT that was about fivefold lower than that found in the VAT of patients with the wild haplotype (P ¼ 0.033; Figure 4a ). On the contrary, when the analysis was carried out separately for each single new variant significant changes on AGT expression in kidney and fat were not found (Figures 4b and c) , although lesser AGT expression in VAT was found in À175A or À163A SNP carriers.
Anti-hypertensive therapy with ACEI/ARBs did not significantly influence AGT expression in any tissue when compared with patients not taking drugs (Table 3) .
There were no significant differences in allele and genotype distributions between hypertensive and normotensive patients, although the À20C variant seemed to have a trend towards an increased prevalence in hypertensive patients (P ¼ 0.071, Table 3 ). Owing to the known large variability of BP, the lack of significant associations is probably 
Discussion
In this study, we have evaluated the association of known and new AGT promoter variants with AGT expression in human kidney and adipose tissue, which are of key importance as a systemic AGT source and/or for the local effects of AGT-derived AngII. Our results support the hypothesis that human AGT promoter variants influence transcriptional activity in vivo, probably by altering the binding of transcription factors. Moreover, the effects of the SNPs studied are tissue-specific, supporting a cell-type-specific transcriptional effect of distinct promoter variants. Indeed, the À20C variant is associated with a more than threefold higher AGT expression than the À20A variant in the kidney medulla but not in the kidney cortex or VAT. This result is in agreement with an earlier study that showed increased promoter activity when the À20C variant was present in the construct used to verify the effect of promoter polymorphisms in a human kidney cell line. 10 Increased AGT gene expression in human kidney medulla may lead to higher local AGT and AngII that, acting directly even on the distal tubule, 15 increases sodium reabsorption and blood pressure. It is well established that locally produced AngII in specific kidney compartments has an important regulatory influence on renal haemodynamics and sodium reabsorption. 19, 20 Recent studies describing higher concentration of AngII in specific regions within the kidney point to the existence of a selective local regulation of intrarenal AngII independently of circulating AngII concentrations. 18 We have also identified two new AGT promoter variants (À175A and À163A) that seem to selectively downregulate AGT expression in human VAT. These variants were not described in the extensive work of Nakajima et al. 21 perhaps because they sequenced the full AGT gene of Africans, Eurasian and East Asians but not Caucasians. In the original work of Jeunemaitre et al., using single-strand conformational polymorphism (SSCP) assay to identify the AGT promoter variant, the AGT promoter involving À175 and À163 regions have not been analysed because of the design of the consecutive primers that overlapped in this region. 22 The proximity and the linkage of these two new SNPs suggest that they probably act by destabilizing the binding of specific nuclear factors. It is interesting that the À175 and À163 variants correspond to a known transcription factor binding site (localized from À173 to À164), classified as an acute-phase responsive element (APRE). Sherman and Brasier 24 have shown that the region that contains the APRE-3 site is transactivated by IL-6 treatment and suggested that APRE-3 may be an important contributor of promoter activity. It is also important to note that APRE-3 site is conserved between rat and human AGT gene, suggesting an important role of this site in transcriptional regulation during evolution. The low-grade systemic inflammation that was likely to be present in our patients with renal intracapsular cancer might have enhanced AGT transcription because AGT is an acute-phase response protein. This factor probably helped in finding such a large difference in AGT expression in the presence of À175A and À163A variants.
In our study, the other well-known promoter variants were not associated with kidney or VAT AGT mRNA levels in vivo. In vitro studies showed that not only À20 but also À217 SNPs have a large influence on AGT transcription in an adipose cell line (3T3-L1). 10 Nevertheless, transfection studies using human adipocytes are needed to confirm both the earlier findings and the potential role of the new human variants we have identified. The lack of association between the GÀ6A variant and blood pressure or cardiovascular phenotype that we have reported earlier 6 has now a new likely explanation on the basis of the findings of this work. Moreover, a very recent meta-analysis encompassing 26 818 patients confirmed the lack of association between the GÀ6A variant and hypertension. 7 Nevertheless, we cannot exclude the possibility that both À217 and -6 SNPs might have a transcriptional effect on AGT expression in other cell types such as liver cells or neurons.
In summary, our results, for the first time, strongly support the hypothesis that some human AGT promoter variants may either predispose to or protect from hypertension by distinct and tissuespecific alteration of AGT expression levels in the kidney and adipose tissue. Moreover, both AGT and Ang II are increased in central obesity. The evidence that adipocytes can produce substantial amounts of AGT has supported the concept that increased adiposity can significantly contribute to inappropriately normal or even elevated plasma renin activity. 25, 26 Ang II itself, through type 1 receptors (AT1), was proposed as a trophic factor in adipose tissue growth and development; 27 indeed, Ang II stimulates lipogenesis 28 and pre-adipocyte differentiation. 29 Some limitations of this study should be taken into account. First, although this study was focused only on the relationships among different AGT promoter variants (including new ones) and AGT mRNA levels in different portions of the human kidney and adipose tissue, the quantification of AGT protein level in these tissues could have enhanced the results and the lack of Western data is a limitation. Nevertheless, although increased AGT mRNA is not obviously the same as increased AGT protein and AngII production, the published body of evidence indicates that AGT protein and AngII production is consensual to tissue mRNA levels both in kidney and adipose tissue. [12] [13] [14] Second, the new variants were more rare in the general population than in our patients, probably because of chance depending on the relatively small number of patients with kidney cancer that we were able to recruit. Third, these new variants should be tested in an appropriate human cell system to study AGT transcription rate, and also to exclude the eventuality that other linked variants were responsible for the effect.
In conclusion, the AGT gene is abundantly expressed in human VAT and, at lower levels, in human kidney. Our results suggest that some AGT promoter variants may influence AGT transcriptional activity in vivo. The À20C variant may result in increased sodium reabsorption, whereas obese patients with the À175A and À163A variants might be protected from the adipose-derived AGT increase, contributing to explain why not all obese patients have increased blood pressure. It is also possible that genetic-based (À175A and À163A-dependent) 'protection' from excessive adipose-derived AGT may help in preventing obesity-related hypertension. Further studies are needed to evaluate the frequencies of the new AGT SNPs in different populations and their association with blood pressure, as well as the postulated AngII-dependent and adipocyte-mediated metabolic complications of overweight. What is known about this topic: K The most well-studied AGT promoter variants are: GÀ217A, AÀ20G, AÀ6G. K Promoter variants have been shown to affect AGT transcription, and variants with increased transcription in vitro have also been associated with essential hypertension in case-control studies.
What this study adds: K This study correlates the presence of known and new AGT promoter SNPs with the level of AGT expression in human tissues of known relevance regarding sodium handling and blood pressure regulation and/or as an important extrahepatic source of systemic AGT (kidney cortex, kidney medulla and visceral adipose tissue (VAT)). K Among the known AGT promoter variants and haplotypes, only the AÀ20C SNP has an important effect on tissuespecific differential AGT expression only in the human kidney medulla. K Two new AGT SNPs (GÀ175A and GÀ163A) influenced AGT expression, but only in human VAT.
